Función pulmonar y proteína catiónica del eosinófilo en la bronquiolitis: estudio en la fase aguda de la bronquiolitis y durante el año posterior
Loading...
Download
Official URL
Full text at PDC
Publication date
2015
Defense date
16/02/1999
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidad Complutense de Madrid
Citation
Abstract
Objetivos: 1. Evaluar las características clínicas, la función pulmonar basal (PRE) y post-broncodilatador (POST) y los niveles de la proteína catiónica del eosinófilo (ECP) de los lactantes en la bronquiolitis. 2. Observar si existe correlación entre la clínica, la función pulmonar y los niveles séricos de la ECP durante el año posterior a la bronquiolitis. Material y métodos: grupo de estudio: 35 lactantes con bronquiolitis (62% varones) de 137±87 dias de edad, 88% VRS. Estudios realizados: En la fase aguda, a los 4, 6 y 12 meses de la bronquiolitis: 1. Puntuación clínica basal RDAI (Repiratory Distress Assessment Instrument) PRE y POST y número de crisis de broncoespasmo en el año posterior 2. Pruebas de función pulmonar: espiración parcial forzada con chaquetilla neumática VmaxFRC (flujo espiratorio máximo a nivel de la capacidad residual funcional) PRE y POST. 3. Niveles en suero de ECP. Resultados 1. Puntuación clínica RDAI en la fase aguda y evolución en el año posterior. RDAI (VN: 0) PRE 6,4±1,3 POST: 8,6±3,2 (p=0,00004). Evolución a los 4 meses: número de crisis 1,4±1,7; entre 4-6 meses: 0,4±0,7; entre 6-12 meses 1,1±2. Función pulmonar: fase aguda PRE: VmaxFRC (VN: ≥ 60%) 31,7%±15 POST: 22,3±8 (p= 0,0003). A los 4 meses: PRE 52,5±19,4; POST 47±20. A los 6 meses: PRE 57,5 ±23,8; POST 58±23. A los 12 meses: PRE 58,8±18,6; POST 56±21 ECP sérica: 20,14±16 (VN: <20 mcg/L). A los 12 meses: 26,8±17. Conclusiones: 1. Se observa un empeoramiento clínico después de la aplicación del salbutamol, estadísticamente significativo. 2. VmaxFRC está muy disminuido en la bronquiolitis, empeorando tras broncodilatador, estadísticamente significativo. 3. Los niveles de ECP se encuentran en límites normales en la bronquiolitis y al año. 4. La puntuación clínica RDAI en la bronquiolitis guarda una relación estadísticamente significativa con la VmaxFRC. 5. La VmaxFRC mejora a los 4 meses de la bronquiolitis, estadísticamente significativo. Estos valores no llegan a normalizarse a los 12 meses
Objectives: 1. To evaluate the clinical manifestation, baseline pulmonary function test (PRE) and post-bronchodilator (POST) and levels of eosinophil cationic protein (ECP) in infants with bronchiolitis. 2. To search if there is a correlation between clinical, pulmonary function test and serum levels of ECP during the year after bronchiolitis. Methods: Study group: 35 infants with bronchiolitis (62% male) of 137 ± 87 days of age, 88% VRS. Studies: In the acute phase, and werw followed at 4, 6 and 12 months of bronchiolitis: 1. RDAI baseline clinical score (repiratory Distress Assessment Instrument) PRE and POST and number of bronchospasm in the subsequent year 2. Pulmonary function test: by means of partial forced expiratory flow-volume manoeuvres performed with an inflatable jacket. Maximum flow at functional residual capacity (FRC) (VmaxFRC) PRE and POST. 3. Serum levels of ECP. Results: 1. Clinical Score RDAI in acute and evolution phase in the subsequent year. RDAI (VN: 0) PRE POST 6.4 ± 1.3 8.6 ± 3.2 (p = 0.00004). Evolution 4 months: number of episodes of whezzing 1.4 ± 1.7; 4-6 months: 0.4 ± 0.7; 6-12 1.1 ± 2 months. VmaxFRC (VN: ≥ 60%) PRE acute phase: 31.7% ± 15 POST: 22.3 ± 8 (p = 0.0003). At 4 months: PRE 52.5 ± 19.4; POST 47 ± 20. At 6 months: PRE 57.5 ± 23.8; POST 58 ± 23. At 12 months: PRE 58.8 ± 18.6; POST 56 ± 21 serum ECP: 20.14 ± 16 (VN: <20 mcg / L). At 12 months: 26.8 ± 17. Conclusions: 1. clinical worsening after application of albuterol is observed statistically significant. 2. VmaxFRC is greatly diminished in bronchiolitis, worse after bronchodilator statistically significant. 3. ECP levels are within normal limits in bronchiolitis and a year. 4. The clinical score RDAI in bronchiolitis keeps a statistically significant relationship with VmaxFRC. 5. VmaxFRC improvement at 4 months of bronchiolitis statistically significant. These values do not come back to normal at 12 months
Objectives: 1. To evaluate the clinical manifestation, baseline pulmonary function test (PRE) and post-bronchodilator (POST) and levels of eosinophil cationic protein (ECP) in infants with bronchiolitis. 2. To search if there is a correlation between clinical, pulmonary function test and serum levels of ECP during the year after bronchiolitis. Methods: Study group: 35 infants with bronchiolitis (62% male) of 137 ± 87 days of age, 88% VRS. Studies: In the acute phase, and werw followed at 4, 6 and 12 months of bronchiolitis: 1. RDAI baseline clinical score (repiratory Distress Assessment Instrument) PRE and POST and number of bronchospasm in the subsequent year 2. Pulmonary function test: by means of partial forced expiratory flow-volume manoeuvres performed with an inflatable jacket. Maximum flow at functional residual capacity (FRC) (VmaxFRC) PRE and POST. 3. Serum levels of ECP. Results: 1. Clinical Score RDAI in acute and evolution phase in the subsequent year. RDAI (VN: 0) PRE POST 6.4 ± 1.3 8.6 ± 3.2 (p = 0.00004). Evolution 4 months: number of episodes of whezzing 1.4 ± 1.7; 4-6 months: 0.4 ± 0.7; 6-12 1.1 ± 2 months. VmaxFRC (VN: ≥ 60%) PRE acute phase: 31.7% ± 15 POST: 22.3 ± 8 (p = 0.0003). At 4 months: PRE 52.5 ± 19.4; POST 47 ± 20. At 6 months: PRE 57.5 ± 23.8; POST 58 ± 23. At 12 months: PRE 58.8 ± 18.6; POST 56 ± 21 serum ECP: 20.14 ± 16 (VN: <20 mcg / L). At 12 months: 26.8 ± 17. Conclusions: 1. clinical worsening after application of albuterol is observed statistically significant. 2. VmaxFRC is greatly diminished in bronchiolitis, worse after bronchodilator statistically significant. 3. ECP levels are within normal limits in bronchiolitis and a year. 4. The clinical score RDAI in bronchiolitis keeps a statistically significant relationship with VmaxFRC. 5. VmaxFRC improvement at 4 months of bronchiolitis statistically significant. These values do not come back to normal at 12 months
Description
Tesis inédita de la Universidad Complutense de Madrid, Facultad de Medicina, Departamento de Pediatría, leída el 16-02-1999